CTX Stock Overview
Captor Therapeutics spolka akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
Captor Therapeutics spolka akcyjna Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł137.00|
|52 Week High||zł209.00|
|52 Week Low||zł127.50|
|1 Month Change||-14.64%|
|3 Month Change||-24.31%|
|1 Year Change||-19.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-20.34%|
Recent News & Updates
|CTX||PL Biotechs||PL Market|
Return vs Industry: CTX exceeded the Polish Biotechs industry which returned -39% over the past year.
Return vs Market: CTX exceeded the Polish Market which returned -42.2% over the past year.
|CTX Average Weekly Movement||7.0%|
|Biotechs Industry Average Movement||7.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in PL Market||13.4%|
|10% least volatile stocks in PL Market||4.5%|
Stable Share Price: CTX is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CTX's weekly volatility (7%) has been stable over the past year.
About the Company
Captor Therapeutics spolka akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. It has five projects at the preclinical stage. The company was founded in 2015 and is based in Wroclaw, Poland.
Captor Therapeutics spolka akcyjna Fundamentals Summary
|CTX fundamental statistics|
Is CTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTX income statement (TTM)|
|Cost of Revenue||zł0|
Last Reported Earnings
Next Earnings Date
May 30, 2022
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did CTX perform over the long term?See historical performance and comparison
Is Captor Therapeutics spolka akcyjna undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
In this section, we usually try to help investors determine whether Captor Therapeutics spolka akcyjna is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Captor Therapeutics spolka akcyjna has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Captor Therapeutics spolka akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Captor Therapeutics spolka akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Captor Therapeutics spolka akcyjna performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Captor Therapeutics spolka akcyjna has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Captor Therapeutics spolka akcyjna's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
In this section we usually analyse Captor Therapeutics spolka akcyjna's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Captor Therapeutics spolka akcyjna has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Captor Therapeutics spolka akcyjna current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Dr. Thomas Shepherd, Ph D also known as Tom, is CEO at Captor Therapeutics spolka akcyjna and serves as Executive Chairman of Captor Therapeutics's Swiss affiliate, with responsibility for global business...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Captor Therapeutics spolka akcyjna's employee growth, exchange listings and data sources
- Name: Captor Therapeutics spolka akcyjna
- Ticker: CTX
- Exchange: WSE
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł569.743m
- Shares outstanding: 4.16m
- Website: https://www.captortherapeutics.com
- Captor Therapeutics spolka akcyjna
- ul. Dunska 11
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.